Fibrillarin is one of four proteins known to interact selectively with all Box C/D family small nucleolar (sno) 1 RNAs (1-6). In eukaryotes, large numbers of snoRNAs direct cleavages and specific nucleotide modifications of pre-rRNA that are required for ribosome biogenesis (7-11). Most Box C/D family snoRNAs guide the site-specific 2Ј-O-methylation of rRNA (12, 13) . snoRNAs function as RNA-protein complexes known as small nucleolar ribonucleoprotein particles (snoRNPs) (11, 14) .
Fibrillarin is one of four proteins known to interact selectively with all Box C/D family small nucleolar (sno) 1 RNAs (1-6). In eukaryotes, large numbers of snoRNAs direct cleavages and specific nucleotide modifications of pre-rRNA that are required for ribosome biogenesis (7) (8) (9) (10) (11) . Most Box C/D family snoRNAs guide the site-specific 2Ј-O-methylation of rRNA (12, 13) . snoRNAs function as RNA-protein complexes known as small nucleolar ribonucleoprotein particles (snoRNPs) (11, 14) .
Fibrillarin has sequence and structural homology to known methyltransferases (15, 16) . This observation, coupled with functional studies in yeast (17) , has led to the hypothesis that fibrillarin is the catalytic factor in Box C/D snoRNA-directed 2Ј-O-methylation of ribosomal RNA.
The survival motor neuron (SMN) protein is linked with one of the most common inheritable causes of childhood mortality, spinal muscular atrophy (SMA) (18 -21) . The SMN1 gene is deleted or mutated in patients with SMA (22) resulting in loss of spinal motor neurons accompanied by progressive muscular atrophy.
SMN has been implicated in an array of cellular pathways. Antibody inhibition experiments have demonstrated that SMN is required for the biogenesis of spliceosomal small nuclear RNPs (snRNPs) (23, 24) , and studies using in vitro splicing systems and yeast mutants have demonstrated a key role for SMN in pre-mRNA splicing (25) (26) (27) . SMN has also been implicated in regulation of gene expression at the transcriptional level (28, 29) , in the assembly of the polymerase II transcription machinery (30) , and as a neuron-specific anti-apoptotic factor (31) (32) (33) .
To learn more about snoRNP biogenesis and structure, we performed a yeast two-hybrid screen for proteins that interact with Xenopus fibrillarin. We identified the survival motor neuron (SMN) gene multiple times in screens of both Xenopus and human cDNA libraries. Fibrillarin had been detected previously in a two-hybrid screen using SMN (34) . We have now demonstrated an in vivo interaction between SMN and fibrillarin, and we show that the two proteins interact directly in vitro. We have mapped the domains of each protein responsible for the interaction, and we found that SMN interacts with fibrillarin and the SmB snRNP protein via the same domain. Our findings suggest a function for SMN in the biogenesis and/or function of snoRNPs (similar to its established role with snRNPs (23-26, 35, 36) ).
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screens-The yeast strain PJ69-4A (MATa, 112, gal4⌬ , gal80⌬, GAL2-ADE2, LYS2::GAL1-HIS3, met2::GAL7-lacZ, generously provided by Phil James, University of Wisconsin) was used for both two-hybrid screens. Xenopus fibrillarin (37) in pGBT9 was used to screen both a Xenopus (CLONTECH) and HeLa cell (generously provided by William Marzluff, University of North Carolina) cDNA GAL4 fusion library. Transformants were screened on media deficient in histidine or adenine and were tested for ␤-galactosidase activity using a liquid colorimetric assay (CLONTECH). Library constructs were recovered from yeast that expressed all three reporter genes and sequenced. Reporter gene expression was confirmed with recovered constructs following co-transformation specifically with the fibrillarin bait construct.
HeLa Cell Co-immunoprecipitation Assay-HeLa S3 cells (ATCC) were cultured by standard procedures. Preparation of nucleolar extracts was essentially as described previously (38, 39) with a modified lysis buffer (10 mM Tris-HCl (pH 7.5), 10 mM KCl, 2 mM MgCl 2 , 0.05% Triton X-100, 1 mM dithiothreitol, protease inhibitor mixture (Roche Molecular Biochemicals)). Approximately two confluent, 10-cm HeLa cultures were used for each immunoprecipitation. Nonidet P-40 (Sigma) was added to nucleolar extract to a final concentration of 0.65%. IgG from the hybridoma cell line SP2/0 (courtesy of Serafin Pinol-Roma, Mount Sinai School of Medicine) and the monoclonal anti-fibrillarin antibody 72B9 (40) were coupled to protein-A-Sepharose (Sigma) equilibrated in IP buffer (20 mM Tris (pH 7.5), 300 mM NaCl, 1 mM EDTA, 0.65% Nonidet P-40). The coupled protein A-Sepharose was incubated with nucleolar extracts (or an equivalent amount of IP buffer) for 2 h at 4°C, and washed 5 times for 5 min with 1 ml of cold IP buffer. Immunoblotting was carried out with the anti-SMN monoclonal antibody 7B10 (27) at 1:1000. Detection was by ECL (Amersham Pharmacia Biotech).
Preparation of Recombinant and in Vitro Translated Proteins-Fulllength cDNA clones encoding Xenopus fibrillarin (37) and SMN (obtained in our two-hybrid screens) as well as human U1A (generously provided by Walther van Venrooij, University of Nijmegen) were subcloned into the glutathione S-transferase (GST) fusion expression vector, pZEX, in which the multiple cloning site of pGEX-2T (Amersham Pharmacia Biotech) was modified to shift the reading frame. 2 Proteins were expressed in Escherichia coli strain BL21 (room temperature induction, 5 h, 1 mM isopropyl-1-thio-␤-D-galactopyranoside) and purified using glutathione-agarose (Pierce). His 6 -, GST-, and zz (two IgGbinding domains)-tagged human SMN constructs were prepared as described previously (23) . His-and zz-tagged proteins were purified by Ni 2ϩ chelation (Qiagen) and IgG-Sepharose (Amersham Pharmacia Biotech) affinity chromatography, respectively. The SMN-Tudor construct 83/173 was a kind gift of Dr. Michael Sattler (see Ref. 41) . SMN-Tudor 83/173 constructs with single amino acid replacements were generated by recombinant polymerase chain reaction. The polymerase chain reaction products were cloned via NcoI/KpnI into a modified pET24d expression vector (Novagen) containing an N-terminal His 6 -GST tag followed by a TEV protease cleavage site (48) and sequenced. Expression and purification was carried out as described (25, 48) .
In vitro translation was carried out using a rabbit reticulocyte lysate, coupled in vitro transcription and translation kit (Promega), and [ . Xenopus fibrillarin and SMN and human U1A were translated from an SP64TEN vector (42) that we re-engineered to include a His 6 , N-terminal fusion tag and a Kozak sequence. SmB and Sip1 were translated from pET vectors as described previously (23) .
In Vitro Binding Assays-For binding assays involving two tagged recombinant proteins, E. coli cell pellets were resuspended in Ipp-250T (50 mM Tris (pH 7.5), 250 mM NaCl, 0.05% Triton X-100), mixed, and sonicated. Extracts were centrifuged at 20,000 ϫ g for 30 min, and the supernatants were incubated with 200 l of glutathione-agarose (Pierce), 1-2 h at 4°C. Pellets were washed 5 times with 1 ml of Ipp-250T and resuspended in SDS sample buffer. Adjustments based on 2 Z. Paroush, unpublished data. . B, recombinant SMN co-purifies from E. coli extracts with GST-fibrillarin. GST-tagged proteins were purified, and co-purified SMN was detected by immunoblotting with antibody 7B10. Glutathione-agarose (beads), GST tag alone, and GST-U1A fail to associate with SMN. Corresponding Coomassie-stained protein gels are included in this and all subsequent figures to show that approximately equal amounts of tagged proteins were used in the assays. Scanned protein bands of different mobilities were aligned in these panels.
Coomassie staining were made to obtain equivalent loading of tagged proteins. Co-purified proteins were analyzed by immunoblotting with anti-SMN monoclonal antibody 7B10.
For binding assays with in vitro translated proteins, similar amounts (based on Coomassie staining) of GST (or zz-)-tagged proteins were coupled to the appropriate resin equilibrated in Ipp-250T. In vitro translated proteins were added (1-3 l) and incubated for 1 h at 4°C in a final volume of 500 l. Following five 1-ml washes with Ipp-250T, the bound proteins were eluted with SDS sample buffer and analyzed by fluorography. The data shown in Fig. 6 were quantitated by densitometric scanning of three separate experiments using a Bio-Rad Fluor-S multi-imager with Quantity 1 software.
RESULTS
Fibrillarin Interacts with SMN in the Yeast Two-hybrid System-Yeast two-hybrid screens were performed to identify proteins that interact with the core Box C/D snoRNP protein fibrillarin. Separate screens were performed with full-length Xenopus fibrillarin against a Xenopus laevis and a human (HeLa) cDNA. The screen of the Xenopus library resulted in isolation of 7 SMN clones from a bank of 4.8 ϫ 10 6 transformants. These clones all coded for either full-length Xenopus SMN or a protein lacking only the first 10 amino acids. The amino acid sequence of Xenopus SMN isolated in our screen is shown in Fig. 1B . When Xenopus fibrillarin was used to screen a human (HeLa cell) cDNA library, the human SMN gene was isolated 21 times among the 1.49 ϫ 10 7 transformants screened. Reporter gene activation was only observed for strains containing both the fibrillarin (XFib-BD) and SMN (Xenopus XSMN-AD or human HSMN-AD) constructs (Fig.  1A) ; the fibrillarin or SMN constructs alone did not activate reporter gene expression (Fig. 1A) . The reciprocal two-hybrid interaction has also been detected using full-length human SMN in a two-hybrid screen of a human cDNA library (34) . The interaction of fibrillarin and SMN in the yeast two-hybrid system suggested the possibility that the proteins interact directly or indirectly in vivo.
Fibrillarin Interacts with SMN in Vivo and in Vitro-We have investigated whether fibrillarin interacts with SMN in vivo in co-immunoprecipitation experiments using HeLa cell extracts. Nuclear extracts enriched in nucleolar material were prepared from HeLa cells. Immunoblot analysis showed that essentially 100% of cellular fibrillarin and ϳ5% of cellular SMN were present in the nucleolar-enriched extracts (data not shown). The antibody 72B9 (40) was used to immunoprecipitate fibrillarin from HeLa cell extracts. Co-precipitation of SMN was assessed by immunoblotting with monoclonal antibody 7B10 against SMN (27) . SMN was co-immunoprecipitated from the HeLa extracts by the anti-fibrillarin antibody ( Fig.  2A) showing that fibrillarin and SMN exist together in a complex in vivo. A mock immunoprecipitation performed without HeLa extract reveals that the other bands are contributed by the antibody (Fig. 2A) . Non-immune IgG (SP2/0) failed to coimmunoprecipitate SMN (Fig. 2A ). These results demonstrate that fibrillarin and SMN are associated in vivo in HeLa cells.
To determine whether fibrillarin and SMN interact directly or indirectly (i.e. as parts of a complex bridged by other components), the interaction of recombinant fibrillarin and SMN was tested in vitro. Recombinant proteins were expressed in E. coli; extracts were mixed; GST-tagged fibrillarin was purified; and co-purification of recombinant SMN was analyzed by immunoblotting with antibody 7B10. SMN specifically co-purified with GST-tagged fibrillarin but not with glutathione-agarose, GST tag alone, or GST-U1A (U1 snRNA-binding protein) (Fig.  2B) . These results indicate that the interaction between fibrillarin and SMN is direct and is not mediated by other eukaryotic protein components.
In Vitro Binding Properties of Fibrillarin and SMN-The strength and specificity of the interaction between SMN and fibrillarin were further characterized using tagged recombinant proteins and in vitro translated 35 S-labeled proteins. GST-tagged SMN (either Xenopus or human SMN, results were not distinguishable) or GST-tagged fibrillarin were expressed in E. coli and coupled to glutathione-agarose. The proteincoupled beads were incubated with in vitro translated 35 Slabeled proteins and washed extensively. Bound labeled proteins were analyzed by SDS-polyacrylamide gel electrophoresis and fluorography. The fibrillarin/SMN interaction occurred in a reciprocal manner, with GST-tagged SMN specifically binding fibrillarin, and GST-tagged fibrillarin specifically binding SMN (Fig. 3A) . GST-tagged SMN interacted with itself, the snRNP-protein SmB, and SIP1/Gemin2, as demonstrated previously (23, 34, 35, 43) , but not with GST tag alone or the U1-binding protein U1A (Fig. 3A and data not shown) . We show here that fibrillarin also self-associates (as suggested previously (16)) but did not interact with GST tag alone, SmB, SIP1/Gemin2, or the U1A protein (Fig. 3A and data not shown) . Approximately equivalent amounts of GST-tagged proteins were used in these assays, as judged by Coomassie-stained gels (Fig. 3A) .
To characterize further the interaction between SMN and 35 S-labeled proteins (fibrillarin, SMN, SmB, and U1A) were incubated with tagged recombinant proteins (GST alone, GST-SMN, or GSTfibrillarin). Tagged proteins were purified, and co-purified proteins were detected by autoradiography. GST-tagged SMN specifically interacts with fibrillarin and SmB but not the unrelated control protein, U1A. GST-tagged fibrillarin specifically precipitates SMN and itself but fails to precipitate SmB and U1A. GST tag alone is included to control for nonspecific binding. In this and all subsequent figures, input lanes (Input) represent 10% of the total amount of in vitro translated protein used in each binding reaction. B, the interaction between SMN and fibrillarin is resistant to high salt. In vitro translated 35 S-labeled fibrillarin was incubated with tagged recombinant GST-SMN at various concentrations of NaCl. GST-SMN was purified, and co-purified fibrillarin was detected by autoradiography. fibrillarin, the assay was carried out in the presence of increasing salt concentrations (Fig. 3B) . The interaction between tagged SMN and in vitro translated fibrillarin was observed in the presence of up to 1 M NaCl. Similarly, the interaction between GST-tagged fibrillarin and in vitro translated SMN was stable to 1 M NaCl washes (data not shown). These results indicate that hydrophobic interactions are important for the association of fibrillarin and SMN.
FIG. 3. In vitro binding properties of SMN and fibrillarin. A, fibrillarin and SMN interact specifically in vitro. In vitro translated
Mapping the SMN Binding Domain of Fibrillarin-Eukaryotic fibrillarin consists of two major domains (Fig. 4A) . The glycine/arginine-rich (GAR) domain consists of ϳ83 amino acids at the N terminus of Xenopus fibrillarin. Based on x-ray structural data and sequence conservation, the rest of the protein (amino acids 83-323) is similar to known SAM-dependent methyltransferases (15, 16) . To determine the domains of fibrillarin that mediate its interaction with SMN, four GSTtagged fibrillarin truncation mutants (Fig. 4A) were expressed in E. coli, coupled to glutathione-agarose, and incubated with full-length, in vitro translated, 35 S-labeled SMN. Binding was assessed following SDS-polyacrylamide gel electrophoresis and fluorography. Deletion of the GAR domain of fibrillarin resulted in a loss of SMN binding (Fig. 4B) . Furthermore, the GAR domain alone interacted with SMN to an extent similar to full-length fibrillarin (Fig. 4B) . These results indicate that the GAR domain of fibrillarin is both necessary and sufficient for association with SMN in vitro.
Mapping the Fibrillarin Binding Domain of SMN-To elucidate the domain of SMN responsible for its interaction with fibrillarin, we tested eight truncation mutants of SMN (Fig.  5A) . Full-length, in vitro translated fibrillarin was incubated with each of the tagged SMN truncation mutants. It was recently shown that the conserved YG box of SMN (encoded by exons VI and VII) mediates the interaction of SMN with other proteins rich in glycine and arginine (Sm and Lsm proteins) and that the interaction is disrupted by a point mutation found in some SMA patients, Y272C (36, 44) . However, the C-terminal half of SMN including the YG box (159/294) failed to interact with fibrillarin (as did this same region containing the Y272C point mutation) (Fig. 5B) . On the other hand, the Nterminal half of SMN (1/160) supported interaction with fibrillarin comparable to that observed with full-length SMN ( prising the Tudor domain (45, 46) , being of primary importance for the interaction.
Missense Mutations in the Tudor Domain of SMN Affect Fibrillarin Binding-The Tudor domain of SMN has also been found to interact with specific Sm proteins (common components of snRNPs) (23, 41) . Recently, the NMR structure of the Tudor domain of SMN and its association with Sm proteins have been characterized (41) . Based upon the NMR structural analysis, we generated 9 missense mutations in the Tudor domain of SMN (amino acids 83-173, Fig. 1B) , and we tested their effect on association with fibrillarin. We found that amino acids Glu-104, Asp-105, Gln-136, and Leu-142 are important for fibrillarin association with the Tudor domain of SMN (Fig.  6A) . Mutation of these residues (E104K, D105K, Q136A, and L142A) reduced binding by 70 -80%. Alteration of other amino acids within or near the Tudor domain binding pocket (Lys-97, Arg-133, Glu-135, Asn-137, and Ser-143) did not significantly alter fibrillarin binding (Fig. 6A) . The same pattern of sensitivity to the mutations was observed for interaction of the Tudor domain with the core snRNP protein SmB, although the degree of the effects was greater for SmB binding than for fibrillarin (Fig. 6A) . Our results indicate that SMN interacts with core components of snoRNPs and snRNPs via similar mechanisms involving the Tudor domain.
Spinal muscular atrophy is correlated with deletions and/or mutations within the SMN1 gene (22) . One point mutation found in SMA patients, E134K, maps to the Tudor domain of SMN and was shown to abolish binding to Sm proteins in vitro (23, 41) . We tested the effect of E134K on the interaction of the N-terminal half of SMN (1/160) with fibrillarin, and we found that the mutation decreased binding by ϳ50% (Fig. 6B) . As expected, the SmB protein also failed to interact efficiently with the E134K mutant (Fig. 6B) . The effect of the SMAassociated E134K point mutation on interaction with fibrillarin reveals a potential link between snoRNP biogenesis or function and spinal muscular atrophy.
DISCUSSION
In this work, we have identified and characterized an interaction between the core Box C/D snoRNP protein fibrillarin and the spinal muscular atrophy-linked protein SMN. This finding is of potential importance to our understanding of snoRNP biogenesis as well as the etiology of spinal muscular atrophy. SMN interacts with fundamental components of multiple nuclear RNA-protein complexes as follows: spliceosomal snRNPs (23, 35, 36, 41, 44) , Box C/D snoRNPs (this work), and also Box H/ACA snoRNPs. 3 The interaction of SMN with each of these RNPs occurs by a similar mechanism involving the Tudor domain of SMN (Refs. 23 and 41 and this work) 3 and the glycine/ arginine-rich domains of the RNP proteins (Refs. 34 and 44 and this work). Interaction with SMN is necessary for the assembly of snRNPs (23, 24) , and the similarities that we have found suggest that SMN also plays an essential role in the biogenesis of snoRNPs.
The interaction that we have found between fibrillarin and SMN in vivo ( Fig. 2A) likely occurs in nucleoli and/or Cajal bodies. Fibrillarin is found primarily in nucleoli where snoRNPs function and also in Cajal bodies where it has been proposed that snoRNP (and snRNP) assembly and biogenesis occur (11, (47) (48) (49) (50) (51) (52) (53) (54) . In adult tissues, SMN is also present in Cajal bodies (54 -58) (although in most fetal tissues and some cultured cell types SMN is found in distinct nuclear structures termed gems (34, 58, 59) ). In addition, there is evidence that SMN is present in nucleoli (55, 57, 58, 60, 61) . We found ϳ5% of total SMN in a nucleolar HeLa cell fraction (data not shown). Furthermore, immunoelectron microscopy reveals that SMN and fibrillarin co-localize within the dense fibrillar component of nucleoli in HeLa cells. 4 Moreover, SMN may be present in nucleoli to an even greater extent in primary tissues than in cultured cells (57, 58, 60 GST-tagged proteins were purified, and co-purified fibrillarin or SmB was detected by autoradiography. Co-purification of fibrillarin and SmB was reduced with point mutants E104K, D105K, Q136A, and L142A (compare with wildtype Tudor domain, wt). B, in vitro translated 35 S-labeled fibrillarin or SmB were incubated with purified, recombinant GST-SMN amino acids 1-160 containing a point mutation (E134K) isolated from an SMA patient. The GST-tagged SMN fragment was purified, and co-purified fibrillarin or SmB was detected by autoradiography. Co-purification of fibrillarin and SmB was reduced with E134K relative to the wild-type fragment (wt).
fetal tissues SMN localizes to nucleoli rather than gems (58) . Moreover, in most adult tissues nearly one-half of Cajal bodies (containing SMN) appears to be located within nucleoli (58) . The co-localization of SMN and fibrillarin in Cajal bodies and nucleoli (the sites of snoRNP biogenesis and function, respectively) supports the hypothesis that SMN is involved in the biogenesis and/or function of Box C/D snoRNPs.
We have found that SMN interacts with the GAR domain of fibrillarin (Figs. 4 and 5) , and other studies indicate that SMN also interacts with hnRNP U (34), several Sm and Sm-like (Lsm) proteins (23, 36, 41, 44, 62) , and RNA helicase A (30) via glycine/arginine-rich domains. On the other hand, the interaction between the Caenorhabditis elegans SMN and fibrillarin homologs in a yeast two-hybrid system was found to be independent of the GAR domain of fibrillarin (63) . It is also noteworthy that arginines within the GAR domains of fibrillarin and other proteins are post-translationally converted to N(G),N(G)-dimethylarginines (64 -68) . It will be of importance to determine if arginine dimethylation represents a point of control in the interaction between fibrillarin and SMN.
The domain of SMN that primarily mediates interaction with fibrillarin is a Tudor domain (Fig. 5) . Tudor domains are conserved protein modules of unknown function that are often present in proteins that associate with RNA (45) but which have been predicted to mediate protein-protein interactions (41, 46) . The Tudor domain of SMN also mediates interaction with Sm proteins of the spliceosomal snRNPs (23) . NMR studies indicate that the Tudor domain of SMN folds into a barrellike structure composed of ␤-sheets forming a hydrophobic pocket surrounded by negatively charged residues that interact with the glycine/arginine-rich C-terminal tails of Sm proteins (41) . The point mutations in the Tudor domain of SMN that we found interfere with fibrillarin and SmB binding (Fig. 6 ) are in amino acids whose side chains extend into the binding pocket of the Tudor domain. In particular, Glu-104 and Asp-105 are two of the residues that contribute to the negatively charged binding pocket, and Gln-136 appears to interact directly with an Sm-derived, glycine/arginine-rich peptide (41) . We have also found that SMN interacts with GAR1, a core component of the other major family of snoRNPs (Box H/ACA) via the Tudor domain and that the interaction depends upon the same 4 amino acids. 3 Our data suggest that SMN interacts with glycine/arginine-rich domains of core components of both the snoRNPs (fibrillarin and GAR1) and snRNPs (Sm proteins) by means of the Tudor domain via similar or identical binding mechanisms.
A key question in our understanding of SMA is why mutation of the ubiquitously expressed SMN gene results in selective effects on the motor neurons. SMN appears to be a multifunctional protein and it will be important to determine which of its cellular functions are relevant to SMA. Although we have found that the SMN/fibrillarin interaction in vitro is reduced by a missense mutation in SMN isolated from an SMA patient (Fig. 6) , it cannot be concluded that disruption of this interaction results in SMA. What is now clear is that the potential role of SMN in snoRNP biogenesis and function must be considered with regard to its importance in SMA. Further studies are required to test the hypothesis that SMN functions as a snoRNP assembly factor and to determine if the interaction between fibrillarin and SMN is directly relevant to the defects in the motor neurons of SMA patients.
